Categories
announces Samsung

Samsung announces Galaxy Note 20 phones, its best shot at the new iPhones coming this fall – CNBC

The Samsung Galaxy Note 20 Ultra

Samsung

Samsung on Wednesday announced a bunch of new products, including phones, tablets, a watch and new earbuds. This is typical timing for Samsung, which usually likes to get its best new products out in August before the fall when Apple typically launches its new iPhone and Apple Watch.

Samsung was the largest phone seller in the world until earlier this month, when Canalys analysis said Huawei overtook it by market share. Samsung and Apple dominate sales in the U.S. But these new devices are high-end phones for people willing to spend $999 to $1,299, not mass-market budget phones that help Samsung achieve its huge market share around the world. Still, Samsung’s Note phones are the nicest crop of devices for the year and will compete directly with Apple’s upcoming iPhone 12 phones.

And it’s clear Samsung is going directly after Apple. Apple typically uses its September event to announce its new phones and new Apple Watch, among other things. And Samsung is doing that earlier.

Here’s what you need to know about what Samsung announced.

Galaxy Note 20 and Galaxy Note 20 Ultra

The Samsung Galaxy Note Ultra

Samsung

Samsung’s Galaxy Note 20 and Galaxy Note 20 Ultra phones are the highlight announcements. The Note phones come with Samsung’s stylus, known as the “S Pen,” and typically pack the highest-end hardware Samsung can cram in a device. Like last year, there’s a more affordable Galaxy Note 20 that starts at $999 and a higher-end Galaxy Note 20 Ultra with a slightly larger and sharper screen, a bigger battery and smoother performance that starts at $1,299.

Both phones include 5G connectivity but, as we’ve reported in the past, there’s still not much of a need to rush out and get a 5G phone right now, since most carriers only offer 5G connections in limited areas. Still, if you’re planning to keep your phone for 3 to 4 years, it’s good future-proofing so you’ll get faster speeds down the line after wireless carriers have built out their 5G networks.

Samsung put a big focus on the cameras on both phones, with support for recording in really high 8K resolution, recording from multiple microphones at the same time for clearer audio and improved pictures. But the cameras are slightly different between the models. The Galaxy Note 20 Ultra has an ultra-wide lens for capturing more of a landscape in each shot, a high resolution 108-megapixel camera for increased detail and a zoom lens that provides up to 50x zoom. The Galaxy Note 20 has a 64-megapixel camera in place of the 108-megapixel on the Ultra and supports up to 30x zoom.

And, like in year’s past, there’s improvements to the S Pen stylus, which slips into the corner of the phone. Gestures now let you control the phone from across the room, so you can close apps, open recent apps, capture the screen and take pictures. It also has improved handwriting recognition, new support for syncing notes across your phone, tablets and computers, and easier annotation in PDF documents.

The Galaxy Note 20 and Galaxy Note 20 Ultra will be available for pre-order on Aug. 6 at 12:01 a.m. ET and will ship by Aug. 21.

Galaxy Z Fold 2

Samsung Galaxy Z Fold 2

Samsung

Samsung also announced the Galaxy Z Fold 2. It’s the successor to the original Galaxy Fold, which has screen issues just before launch and was delayed months before it finally came to market. The Galaxy Z Fold 2 has a large 6.2-inch screen on the front. When open, it has a large 7.6-inch foldable display that looks a bit more like a tablet. Samsung didn’t discuss pricing but said it will launch in September.

Galaxy Tab 7, Galaxy Watch 3, Galaxy Buds Live

The Samsung Galaxy Tab S7, Galaxy Watch 3, and Galaxy Buds Live

Samsung

Samsung also announced a bunch of other stuff, including two tablets meant to compete with Apple’s iPad Pro line, including a 12.4-inch Galaxy Tab S7 Plus and an 11-inch Galaxy Tab S7. Both pack 5G connectivity, Google‘s Android operating system, sharp screens and ship with an included stylus that sticks to the back to recharge. The 11-inch model will start at $649, while the larger Tab S7 Plus will start at $849.

Samsung’s new Galaxy Watch 3 and Galaxy Buds Live headphones were also announced. The Galaxy Watch is similar to past models with a rotating bezel that you can use to select apps. Like the Apple Watch, it can detect when you’re working out and automatically log your exercise for you, in case you forget to start it on the device. It can detect blood pressure, too, but only in Samsung’s home country of South Korea since it hasn’t received FDA approval in the U.S. 

The Galaxy Buds Live are similar to Apple’s AirPods Pro. They’re tiny earbuds that charge in their case, but look like little beans that fit right into your ears. They feature noise cancellation, which should help block out background noise while you’re working or walking around town, and you can dial it back if you need to hear what’s going on around you. They’ll cost $169, which is a big discount from the $249 Apple charges for AirPods Pro.

Read More

Categories
announces Moderna

Moderna Announces Expansion of BARDA Agreement to Support Larger Phase 3 Program for Vaccine (mRNA-1273) Against COVID-19 – Yahoo Finance

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) for an additional commitment of up to $472 million to support late stage clinical development including the expanded Phase 3 study of the Company’s mRNA vaccine candidate (mRNA-1273) against COVID-19.

An earlier award from BARDA for up to $483 million was entered into to support the scale up of mRNA-1273 and clinical development, originally with a smaller anticipated number of participants in the Phase 3 clinical trial. Following discussions with the U.S. Food and Drug Administration (FDA) and consultations with Operation Warp Speed over the past several months, the Company has decided to conduct a significantly larger Phase 3 clinical trial, leaving a gap in BARDA funding that will be closed by this contract modification. Under the terms of the revised contract, BARDA is expanding their support of the Company’s late stage clinical development of mRNA-1273, including the execution of a 30,000 participant Phase 3 study in the U.S. The total value of the award is now approximately $955 million.

“We thank BARDA for this continued commitment to mRNA-1273, our vaccine candidate against COVID-19.” said Stéphane Bancel, Moderna’s Chief Executive Officer. “Encouraged by the Phase 1 data, we believe that our mRNA vaccine may aid in addressing the COVID-19 pandemic and preventing future outbreaks.”

ClinicalTrials.gov identifier is NCT04470427.” data-reactid=”27″ type=”text”>The Phase 3 COVE study is being conducted in collaboration with National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) and is expected to begin tomorrow, July 27. The Phase 3 study protocol has been reviewed by the U.S. Food and Drug Administration (FDA) and is aligned to recent FDA guidance on clinical trial design for COVID-19 vaccine studies. The randomized, 1:1 placebo-controlled trial is expected to include approximately 30,000 participants at the 100 µg dose level in the U.S. The primary endpoint will be the prevention of symptomatic COVID-19 disease. Key secondary endpoints include prevention of severe COVID-19 disease (as defined by the need for hospitalization) and prevention of infection by SARS-CoV-2. The ClinicalTrials.gov identifier is NCT04470427.

Moderna is working closely with Operation Warp Speed and the NIH, including NIAID’s COVID-19 Prevention Trials Network (CoVPN), to conduct the Phase 3 COVE study. Working together with collaborators like NIH, the Company hopes to achieve a shared goal that the participants in the COVE study are representative of the communities at highest risk for COVID-19 and of our diverse society.

strategic collaboration with Lonza. In addition, Moderna recently announced a collaboration with Catalent for large-scale, commercial fill-finish manufacturing of mRNA-1273 at Catalent’s biologics facility in Indiana. Initial funding of $1.3 billion for Moderna to begin producing mRNA-1273 supply at-risk was secured from investors in the Company’s most recent public equity offering in May 2020.” data-reactid=”29″ type=”text”>The Company remains on track to be able to deliver approximately 500 million doses per year, and possibly up to 1 billion doses per year, beginning in 2021 from the Company’s internal U.S. manufacturing site and strategic collaboration with Lonza. In addition, Moderna recently announced a collaboration with Catalent for large-scale, commercial fill-finish manufacturing of mRNA-1273 at Catalent’s biologics facility in Indiana. Initial funding of $1.3 billion for Moderna to begin producing mRNA-1273 supply at-risk was secured from investors in the Company’s most recent public equity offering in May 2020.

BARDA is part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services. This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50120C00034.

prefusion stabilized form of the Spike (S) protein, which was selected by Moderna in collaboration with investigators from the VRC. The first clinical batch, which was funded by the Coalition for Epidemic Preparedness Innovations, was completed on February 7, 2020 and underwent analytical testing; it was shipped to NIH on February 24, 42 days from sequence selection. The first participant in the NIAID-led Phase 1 study of mRNA-1273 was dosed on March 16, 63 days from sequence selection to Phase 1 study dosing. On May 12, the FDA granted mRNA-1273 Fast Track designation. Both cohorts, healthy adults ages 18-55 years (n=300) and older adults ages 55 years and above (n=300), in the Company’s Phase 2 study of mRNA-1273 are fully enrolled. A summary of the company’s work to date on COVID-19 can be found here.” data-reactid=”32″ type=”text”>mRNA-1273 is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was selected by Moderna in collaboration with investigators from the VRC. The first clinical batch, which was funded by the Coalition for Epidemic Preparedness Innovations, was completed on February 7, 2020 and underwent analytical testing; it was shipped to NIH on February 24, 42 days from sequence selection. The first participant in the NIAID-led Phase 1 study of mRNA-1273 was dosed on March 16, 63 days from sequence selection to Phase 1 study dosing. On May 12, the FDA granted mRNA-1273 Fast Track designation. Both cohorts, healthy adults ages 18-55 years (n=300) and older adults ages 55 years and above (n=300), in the Company’s Phase 2 study of mRNA-1273 are fully enrolled. A summary of the company’s work to date on COVID-19 can be found here.

Moderna scientists designed the company’s prophylactic vaccines modality to prevent infectious diseases. More than 1,900 participants have been enrolled in Moderna’s infectious disease vaccine clinical studies under health authorities in the U.S., Europe and Australia. Clinical data demonstrate that Moderna’s proprietary vaccine technology has been generally well-tolerated and can elicit durable immune responses to viral antigens. Based on clinical experience across Phase 1 studies, the company designated prophylactic vaccines a core modality and is working to accelerate the development of its vaccine pipeline.

The potential advantages of an mRNA approach to prophylactic vaccines include the ability to combine multiple mRNAs into a single vaccine, rapid discovery to respond to emerging pandemic threats and manufacturing agility derived from the platform nature of mRNA vaccine design and production. Moderna has built a fully integrated manufacturing plant which enables the promise of the technology platform.

nine development candidates in its prophylactic vaccines modality, including:” data-reactid=”40″ type=”text”>Moderna currently has nine development candidates in its prophylactic vaccines modality, including:

  • Respiratory syncytial virus (RSV) vaccine for older adults (mRNA-1777 and mRNA-1172 or V172 with Merck)
  • RSV vaccine for young children (mRNA-1345)
  • Human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3) vaccine (mRNA-1653)
  • COVID-19 vaccine (mRNA-1273)
  • Influenza H7N9 (mRNA-1851)
  • Cytomegalovirus (CMV) vaccine (mRNA-1647)
  • Zika vaccine (mRNA-1893 with BARDA)
  • Epstein-Barr virus (EBV) vaccine (mRNA-1189)
  • To date, Moderna has demonstrated positive Phase 1 data readouts for eight prophylactic vaccines (H10N8, H7N9, RSV, chikungunya virus, hMPV/PIV3, CMV, Zika and COVID-19). Moderna’s CMV vaccine is currently in a Phase 2 dose-confirmation study. Moderna’s investigational Zika vaccine (mRNA-1893), currently in a Phase 1 study, was granted FDA Fast Track designation in August 2019.

    Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. The company’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.

    www.modernatx.com.” data-reactid=”58″ type=”text”>Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, and the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been ranked in the top ten of Science’s list of top biopharma industry employers for the past five years. To learn more, visit www.modernatx.com.

    www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.” data-reactid=”60″ type=”text”>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding the Company’s development of a potential vaccine against the novel coronavirus, the parameters and timing of the P

    Read More

    Categories
    announces Reebok

    Reebok announces it will end partnership with CrossFit after CEO’s insensitive George Floyd tweet – Yahoo Sports

    A single tweet from the founder and CEO of CrossFit has prompted Reebok to announce it will end its relationship with the fitness network by the end of the year. Greg Glassman, who founded the business with his wife in 2000, has since apologized.

    The tweet in question came in response to a statement from the director of the Institute for Health Metrics and Evaluation at the University of Washington.

    The statement called racism a public health issue. Glassman replied with a joke about COVID-19, which the IHM has covered since March. Specifically, he called it “FLOYD-19.”

    Glassman followed that up the next day by criticizing the IHM’s advocacy for quarantines and lamenting national riots.

    Your failed model quarantined us and now you’re going to model a solution to racism? George Floyd’s brutal murder sparked riots nationally. Quarantine alone is “accompanied in every age and under all political regimes by an undercurrent of suspicion, distrust, and riots.” Thanks!

    — Greg Glassman (@CrossFitCEO) June 7, 2020

    A tweet equating a response to systemic racism and police brutality to a global pandemic was bound to draw backlash, and that eventually included one of CrossFit’s biggest corporate partners.

    announced to Footwear News on Sunday that it has ended discussions about extending its partnership with CrossFit and will allow its relationship to come to an end this year:” data-reactid=”25″ type=”text”>Reebok announced to Footwear News on Sunday that it has ended discussions about extending its partnership with CrossFit and will allow its relationship to come to an end this year:

    “Our partnership with CrossFit HQ comes to an end later this year. Recently, we have been in discussions regarding a new agreement, however, in light of recent events, we have made the decision to end our partnership with CrossFit HQ,” Reebok said in a statement emailed to FN. “We will fulfill our remaining contractual obligations in 2020. We owe this to the CrossFit Games competitors, fans and the community.”

    The statement continued, “What doesn’t change is our commitment and dedication to CrossFitters and the passionate CrossFit community. We’re so thankful for the strong bonds we’ve created with coaches, box owners and athletes around the world over the past 10 years. We want to especially thank Dave Castro, Nicole Carroll, Andy Stumpf, Steve Weiss and Jimi Letchford, who were instrumental in ensuring Reebok was welcomed by the community, so that we could do our part to help more people improve their lives through fitness.”

    licensing rights — also questioned the tweet or said they would sever ties with CrossFit.” data-reactid=”28″ type=”text”>Reebok wasn’t alone in severing ties with CrossFit, as a number of gyms — which pay Glassman’s company for licensing rights — also questioned the tweet or said they would sever ties with CrossFit.

    posted Glassman’s reply to an email it had sent questioning his response to the pandemic and protests around Floyd’s death. In an unhinged reply, Glassman questioned the writer’s mental health, called her attitude “disgusting” and deemed her “evil” and “a really s—- person.”” data-reactid=”29″ type=”text”>One CrossFit gym announced it would cease its partnership and posted Glassman’s reply to an email it had sent questioning his response to the pandemic and protests around Floyd’s death. In an unhinged reply, Glassman questioned the writer’s mental health, called her attitude “disgusting” and deemed her “evil” and “a really s—- person.”

    Glassman later released a statement via the @CrossFit Twitter account, saying his choice of words was “not racist but a mistake” and calling for racial justice.

    Floyd is a hero in the black community and not just a victim. I should have been sensitive to that and wasn’t. I apologize for that. I was trying to stick it to the @IHME_UW for their invalidated models resulting in needless, economy-wrecking, life-wrecking lockdown,

    — CrossFit (@CrossFit) June 8, 2020

    It’s our hope that his murder catalyzes real change resulting in a level playing field for our black brothers and sisters.

    Please hear me when I say, we stand by our community to fight for justice. I care about you, our community, and I am here for you.”

    — CrossFit (@CrossFit) June 8, 2020

    fired its chief knowledge officer Russell Berger after he called celebrati

    Read More

    Categories
    announces Colorado

    Colorado announces no new coronavirus-linked deaths for second straight day – Fox News

    Get all the latest news on coronavirus and more delivered daily to your inbox. Sign up here.

    For the second straight day, Colorado reported no new deaths linked directly to the novel coronavirus, according to official estimates.

    COLORADO AMENDS CORONAVIRUS DEATH COUNT – SAYS FEWER HAVE DIED OF COVID-19 THAN PREVIOUSLY REPORTED

    The news comes as deaths from the coronavirus in the Centennial State have continued to decline since peaking in mid-April, the Denver Post reported. 

    Hospitalizations due to COVID-19 are also falling, with some 297 people currently hospitalized in Colorado. The newspaper noted this is the first time since March 27 that less than 300 people in the state have been hospitalized at once due to the coronavirus.

    The news comes after Colorado made a significant change to the way it counts COVID-19 deaths that reduced the statewide figure from more than 1,000 to 878 in mid-May. The change came after Colorado’s Department of Public Health admitted that its COVID-19 death toll was counting those who tested positive for the coronavirus but had died of other causes. The state now separates the two, now listing “deaths among cases” and “deaths due to COVID-19” in separate categories in its official estimates.

    CLICK HERE FOR MORE CORONAVIRUS COVERAGE

    Colorado has reported 26,378 cases of the novel virus, with some 1,181 deaths due to COVID-19, according to the latest estimates. 

    Read More

    Categories
    announces Microsoft

    Microsoft announces supercomputer with human like artificial intelligence – Yahoo Finance











    Published on 19-May-2020

    Microsoft (MSFT) on Tuesday announced that it has built one of the top five supercomputers in the world designed specifically for OpenAI. The company made the announcement during its Build developers conference, which is being held virtually rather than in person in Seattle where it is usually held each year.

    The supercomputer, Microsoft says, will be used to train OpenAI’s own artificial intelligence models. OpenAI, which was founded in 2015 and received initial funding from the likes of Elon Musk and Sam Altman. Musk has since left the company, while Altman is now its CEO.

    The company is working to create artificial general intelligence, or AI that is capable of outperforming humans, according to the group’s charter. The firm says its main concern is that such technologies benefit all of humanity, while ensuring its power doesn’t become concentrated in the hands of a few.

    The new supercomputer has an incredible 285,000 CPU cores, 10,000 graphics processing units, and 400 gigabits per second of connectivity for each GPU server. While the computer ranks in the top five of the most powerful machines in the world, Microsoft won’t say exactly where it falls on that list.

    #Microsoft #ArtificialIntelligence

    Subscribe to Yahoo Finance: https://yhoo.it/2fGu5Bb

    About Yahoo Finance:

    At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

    Connect with Yahoo Finance:

    Get the latest news: https://yhoo.it/2fGu5Bb

    Find Yahoo Finance on Facebook: http://bit.ly/2A9u5Zq

    Follow Yahoo Finance on Twitter: http://bit.ly/2LMgloP

    Follow Yahoo Finance on Instagram: http://bit.ly/2LOpNYz

    Read More

    Categories
    announces Samsung

    Samsung announces 50-megapixel camera sensor with faster autofocus – The Verge

    Samsung has announced a new 50-megapixel camera sensor called the ISOCELL GN1. It’s Samsung’s first sensor to include both dual-pixel autofocus and Tetracell pixel-binning, which the company says should offer a combination of fast performance and good low-light image quality.

    The pixel size is 1.2μm, closer to what you’d find on a conventional phone camera sensor than the high-resolution chips that’ve become increasingly popular over the past year-plus. The obvious competitor is Sony’s new IMX689 sensor, featured in phones like the Oppo Find X2 Pro, which has 48 megapixels at 1.22μm. By default, Samsung’s sensor will take 12.5-megapixel photos with four pixels binned into one.

    The addition of dual-pixel phase-detection autofocus is noteworthy because Samsung had a recent high-profile failure in that area. The Galaxy S20 Ultra, which used a 108-megapixel sensor without dual-pixel tech, suffered from poor autofocus performance; Samsung said it would issue a fix, though we haven’t been able to test for improvements yet.

    In any case, the combination of high resolution and fast autofocus speed is clearly Samsung’s priority with the ISOCELL GN1. The company says the sensor entered mass production this month, so it shouldn’t be too long before it shows up in phones.

    Read More

    Categories
    announces SoftBank

    SoftBank announces that Jack Ma will leave its board ahead of earnings report – CNN

    Hong Kong (CNN Business)SoftBank lost a major name from its board and confirmed historic losses on Monday — signs of turmoil at the Japanese conglomerate after it was battered by the coronavirus pandemic and a series of tech bets gone bad.

    Hours before SoftBank reported a record annual operating loss of 1.36 trillion yen ($12.7 billion) — the worst in at least 20 years, according to the data provider Refinitiv — it announced that Alibaba (BABA) founder Jack Ma would resign from its board. Ma, who is still a director of the Chinese e-commerce company, had held the position for nearly 13 years.
    He’s the latest noteworthy board member to leave, after billionaire and Fast Retailing (FRCOF) founder Tadashi Yanai’s departure at the end of last year.
    Ma’s exit is particularly noteworthy because of his closeness to SoftBank founder and CEO Masayoshi Son. Son invested $20 million in Alibaba in 2000, a bet that was worth $60 billion when Alibaba went public in 2014.
    SoftBank did not explain the reasoning behind Ma’s departure. But the company has been taking dramatic measures to shore up its finances, including a plan to sell $41 billion in assets.
    During the earnings presentation Monday, Son revealed that the company had secured $11.5 billion in funding by doing deals that allow SoftBank to sell Alibaba stock in the future.
    SoftBank’s 25.1% stake in the company is currently worth more than $133 billion.
    It’s been a tumultuous time for SoftBank. The sweeping, worldwide restrictions on work and travel caused by the coronavirus pandemic have walloped the company’s investment portfolio.
    Some of Son’s major tech investments, meanwhile, faced rough receptions on Wall Street long before the outbreak. The losses that SoftBank reported Monday were in line with its own recent forecasts and driven almost entirely by SoftBank’s Vision Fund, the $100 billion tech fund steered by Son.
    SoftBank said the Vision Fund and affiliated funds suffered operating losses of 1.9 trillion ($17.7 billion) for the fiscal year that ended in March. The values of Uber (UBER), WeWork and other portfolio companies fell significantly in the three months to March “primarily due to the impact” of the virus, the company said.
    “If the pandemic continues, the company expects that uncertainty in its investment businesses will remain over the next fiscal year,” SoftBank added.
    Son is trying to right the ship. In March, the company made the surprise announcement that it would sell assets to buy back shares and reduce the company’s heavy debt load.
    The Japanese company on Monday also said it is buying back up to 500 billion yen ($4.7 billion) worth of shares over the next year, the second share purchase of this size since March. More buybacks are likely on the way: The company has said it wants to repurchase up to 2 trillion Japanese yen ($18 billion) in stock.
    Shares in SoftBank closed up 1% in Tokyo, outperforming the broader Nikkei 225 (N225), which ended the day 0.5% higher. The stock has lost 21% since its most recent peak last July.

    Read More

    Categories
    announces Cuomo

    Cuomo announces new testing centers in low-income communities – CBS News














    CBS News




    26.2 lakh


    Want to watch this again later?

    Sign in to add this video to a playlist.

    Sign in


    Like this video?

    Sign in to make your opinion count.

    Sign in



    Don’t like this video?

    Sign in to make your opinion count.

    Sign in



    Published on 09-May-2020

    New York Governor Andrew Cuomo on Saturday announced two dozen new coronavirus testing centers in churches in predominately low-income and minority communities. New York’s largest health system, Northwell Health, will conduct the tests. “The churches will help us outreach to people in the community, and get people to come in and explain to people why it’s important to come in and get tested,” Cuomo said.

    Read More